Eve McLean’s Post

Today, there are an astounding 31,755+ articles published about #exosomes on PubMed.gov, of which the vast majority were recently released. An incredible 21,362 of those publications were published in the past 5 years. This means that two-thirds (67.3%) of all exosome publications were published in the past 5 years, proving to scientists, clinicians, and investors alike that the exosome industry is coming of age—and exploding with potential. Today, exosomes are being explored across a diverse range of therapeutic and diagnostic applications, with particular attention given by the pharmaceutical industry to drug-loaded exosomes. Already, three pharma companies (Roche, Jazz Pharmaceuticals, and Takeda) have signed partnership deals with exosome companies offering payment terms structured to deliver at or around $1 billion dollars. In recent years, there has been at least 7 partnership deals within the exosome industry, 8 large venture capital events, and 2 landmark acquisitions. Globally, there are at least 204 clinical trials focusing on exosome-related studies. Of these, 114 trials are evaluating exosome-based therapeutics and 74 trials are testing exosome-based diagnostic tests. Currently, 93 of the exosome trials (45%) are observational studies and 111 of them (55%) are interventional studies. A surprising 88 (43%) of them are actively recruiting patients. Also, the exosome industry has achieved two FDA-approved diagnostic tests, including Bio-Techne's ExoDx Prostate IntelliScore Test for prostate cancer and Guardant Health's 360 CDx test for lung cancer. Importantly, the ability to engineer exosomes to carry desired drugs and target specific sites opens a new class of therapeutics that do not have the side effects and toxicity associated with small molecule or cell-based therapies. Advantages that make exosomes suitable therapeutic vehicles are their ability to hone to the target tissue, pass through biological barriers, and act as encapsulated drugs that can avoid immune system detection and degradation. Exosome-based diagnostics also offer revolutionary advantages. They are minimally invasive, offer ease of use, facilitate speed of detection, and can act as prognostic indicators for a patient’s response to a specific course of treatment. To characterize the rapidly proliferating exosome market, BioInformant has released a 312-page global strategic report that explores the surging demand for exosome therapeutics, diagnostics, research tools, and manufacturing technologies. The report reveals trend rate data for exosome patents, grants, scientific publications, and clinical trials. It presents information about exosome industry partnerships, M&A activity, IPOs, and financing events. It profiles all known competitors worldwide, presenting their product pipeline, core technologies, and strategic approach. It also presents market size figures by segment with future forecasts. https://lnkd.in/e_yF42j

New on Pharma's Almanac: GBI Bio's Muctarr Sesay, Ph.D., and Natalia Bourguignon, Ph.D. propose an accelerated approach for the production of radioimmune conjugate pharmaceuticals for first-in-human phase 0 proof-of-concept studies. Learn about recent advancements and the enormous potential of theranostics technology as it pertains to radioimmune conjugates for personalized diagnosis and treatment of cancer. #theranostics #Phase0 #radiopharmaceuticals

💡 𝐍𝐨𝐯𝐚𝐫𝐭𝐢𝐬 𝐄𝐱𝐩𝐚𝐧𝐝𝐬 𝐑𝐚𝐝𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐇𝐨𝐫𝐢𝐳𝐨𝐧𝐬 𝐰𝐢𝐭𝐡 𝐚 $𝟕𝟒𝟓𝐌 𝐃𝐞𝐚𝐥! Novartis has entered a strategic licensing agreement with Boston-based Ratio Therapeutics to advance cutting-edge radiopharmaceutical therapies. This deal, worth up to $745M, 𝘨𝘳𝘢𝘯𝘵𝘴 𝘕𝘰𝘷𝘢𝘳𝘵𝘪𝘴 𝘨𝘭𝘰𝘣𝘢𝘭 𝘳𝘪𝘨𝘩𝘵𝘴 𝘵𝘰 𝘥𝘦𝘷𝘦𝘭𝘰𝘱 𝘢 𝘤𝘢𝘯𝘤𝘦𝘳 𝘤𝘢𝘯𝘥𝘪𝘥𝘢𝘵𝘦 𝘵𝘢𝘳𝘨𝘦𝘵𝘪𝘯𝘨 𝘴𝘰𝘮𝘢𝘵𝘰𝘴𝘵𝘢𝘵𝘪𝘯 𝘳𝘦𝘤𝘦𝘱𝘵𝘰𝘳 2 (𝘚𝘚𝘛𝘙2), 𝘭𝘦𝘷𝘦𝘳𝘢𝘨𝘪𝘯𝘨 𝘙𝘢𝘵𝘪𝘰’𝘴 𝘱𝘳𝘰𝘱𝘳𝘪𝘦𝘵𝘢𝘳𝘺 𝘳𝘢𝘥𝘪𝘰𝘭𝘪𝘨𝘢𝘯𝘥 𝘵𝘦𝘤𝘩𝘯𝘰𝘭𝘰𝘨𝘺 𝘱𝘭𝘢𝘵𝘧𝘰𝘳𝘮𝘴. 𝘞𝘩𝘺 𝘛𝘩𝘪𝘴 𝘔𝘢𝘵𝘵𝘦𝘳𝘴: 🔬𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆: Ratio’s radioligand platforms are tailored for both therapeutic and imaging applications, enabling precision oncology. 💊 𝗧𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝘃𝗲 𝗣𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹: The partnership aims to develop a best-in-class therapy for SSTR2-expressing tumours, offering new hope for patients with challenging cancers. 🌍 𝗚𝗹𝗼𝗯𝗮𝗹 𝗜𝗺𝗽𝗮𝗰𝘁: Novartis will lead the development, regulatory, and commercialization processes, ensuring broad access to this promising treatment. Fiona H. Marshall, President of Biomedical Research at Novartis, states: "Radioligand therapies hold transformative potential for certain forms of cancer... We are delighted to collaborate with Ratio to advance this #RLT candidate and bring forward additional therapeutic options for patients with difficult-to-treat cancer." 👉 𝐋𝐢𝐧𝐤 𝐢𝐧 𝐜𝐨𝐦𝐦𝐞𝐧𝐭𝐬 𝐛𝐞𝐥𝐨𝐰! BioPharmaTrend.com #Radiopharmaceuticals #CancerResearch #BiotechInnovation #Novartis #RatioTherapeutics #OncologyBreakthroughs #PrecisionMedicine #StrategicPartnerships #BPT #BPTnews

Thoughts on this? >> Sana strips back cancer, CNS programs as cell therapy biotech warns of further layoffs >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #competitivemarketing #biotech #pharma #healthcare

The radiopharmaceutical market is set to soar! It is projected to grow from $9B in 2023 to $26.5B by 2031! With rising cancer and Alzheimer’s cases, advancements in diagnostics, and demand for targeted treatments, healthcare is evolving fast. North America leads, but Asia-Pacific is catching up. Are we ready to meet the global demand for these cutting-edge therapies?

As the fight against hematologic malignancies intensifies, leading pharmaceutical companies are making significant strides in developing innovative treatments. Here’s a quick snapshot of key players and their contributions to the market: Bristol-Myers Squibb: Pioneering in immunotherapy with promising new treatments that target specific cancer cells. #BristolMyersSquibb Johnson & Johnson: Driving advancements in targeted therapies and personalized medicine. #JohnsonAndJohnson AbbVie: Enhancing treatment options with novel drugs and combination therapies. #AbbVie Novartis: Leading the way with breakthrough therapies for difficult-to-treat hematologic cancers. #Novartis Roche: Developing cutting-edge biologics and targeted therapies for hematologic malignancies. #Roche Amgen: Innovating with novel approaches and biologics to improve patient outcomes. #Amgen Takeda: Focusing on precision medicine and cutting-edge treatments for blood cancers. #Takeda Pfizer: Bringing forward new therapeutic options with a focus on targeted and immuno-oncology treatments. #Pfizer AstraZeneca: Advancing the field with innovative therapies and combination approaches. #AstraZeneca Gilead Sciences: Leading research and development in cell therapies and targeted treatments. #GileadSciences These companies are at the forefront of revolutionizing treatment for hematologic malignancies, each contributing unique solutions to the evolving landscape of cancer care. #HematologicMalignancies #CancerResearch #Oncology #Pharma #Biotech #HealthcareInnovation #MedicalResearch #CancerTreatment #DrugDevelopment #Immunotherapy #PrecisionMedicine #TargetedTherapies Read Report @ https://lnkd.in/gwrRbiqW

This GBI article presents an overview of the recent FDA regulatory guidance on the introduction of Phase 0(zero) application for radioimmune conjugate manufacturing requirements for preliminary diagnosis of diseases in Human POC studies. It will add to the repertoire and as a precursor to Theranostic technology (see, assess and treat the disease) in the near and long term future of many modalities,

Thoughts on this? >> AstraZeneca outlines AI-enabled TROP2 biomarker strategy for Daiichi ADC after limited lung cancer showing >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #healthcare #biotech #competitivemarketing

Today, there are an astounding 28,000+ articles published about #exosomes on PubMed.gov, of which the vast majority were recently released. An impressive 19,611 of those publications were published in the past 5 years. This means that approximately 70% of all exosome publications were published within the past five years, proving to scientists, clinicians, and investors alike that the exosome industry is coming of age—and exploding with potential. Exosomes are now being explored across a diverse range of therapeutic and diagnostic applications, with particular attention being given by the pharmaceutical industry to drug-loaded exosomes. Already, three pharmaceutical companies have signed partnership deals with exosome companies offering up-front, royalty, and milestone payments structured to deliver at or around $1 billion dollars. Within the past 5 years, there have been at least 7 partnership deals within the exosome industry, 8 large venture capital events, and 2 major acquisitions. Globally, there are at least 204 clinical trials focusing on exosome-related studies. Of these, 114 trials are evaluating exosome-based therapeutics and 74 trials are testing exosome-based diagnostic tests. Currently, 93 of the exosome trials (45%) are observational studies and 111 of them (55%) are interventional studies. A surprising 88 (43%) of them are actively recruiting patients. Furthermore, the exosome industry has already provided two FDA-approved diagnostic tests, including: - Bio-Techne's ExoDx Prostate IntelliScore Test for prostate cancer  - Guardant's 360 CDx test for non-small cell lung cancer Importantly, the ability to engineer exosomes to carry desired drugs and target specific sites opens a new class of therapeutics that do not have the side effects and toxicity associated with small molecule-based therapies or cell-based therapies. Some of the advantages that make exosomes suitable therapeutic vehicles are their ability to hone to the target tissue, their ability to pass through biological barriers, and their ability to act as encapsulated drugs that can avoid immune system detection and degradation. Exosome-based diagnostics also offer revolutionary advantages. They are minimally invasive, offer ease of use, facilitate speed of detection, and can act as prognostic indicators for a patient’s response to a specific course of treatment. To characterize the rapidly proliferating exosome market, BioInformant released the "Global Exosome Market – Market Size, Forecast, Trials and Trends." Learn more here: https://lnkd.in/e_yF42j

The antibody-drug conjugates (ADC) contract manufacturing market will grow from $8.72B in 2023 to $14.00B by 2028 at a CAGR of 10.5%, driven by advancements in ADC technologies, personalized medicine, and rising demand for targeted cancer therapies. Key players like Lonza, AbbVie, and MilliporeSigma innovate with solutions like the Mobius ADC Reactor for efficient and scalable ADC production. Read more https://lnkd.in/gpAPGdi5 #AntibodyDrugConjugates #ADCMarketGrowth #PrecisionMedicine #CancerTherapies #BiopharmaInnovation #marketresearch #marketintelligence #marketreport #industryanalysis #TheBusinessResearchCompany #TBRC #GlobalMarketModel